Search

Background Colorectal cancer (CRC) is the third most common malignancy diagnosed in both men and women and the fourth leading cause of cancer-related deaths worldwide. Special AT-rich sequence-binding protein 2 (SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was identified as a highly tissue-type-specific protein being predominantly expressed in glandular cells of the lower gastrointestinal tract. Objective To determine SATB2 expression in CRC, relation of SATB2 expression in CRC with clinicopathological features and to compare its expression with non-colorectal adenocarcinoma including (gastric, hepatobiliary, intestinal and pancreatic cases). Material and Methods Samples from 38 known CRC cases and 41 non-colonic origin adenocarcinomas (gastric, hepatobiliary, intestinal and pancreatic cases) were studied immunohistochemically for SATB2 expression. Results All CRC (38 cases) showed positive SATB2 expression score. More than half of them demonstrated score +3, while (92%) of non-colonic origin adenocarcinoma cases were negative for SATB2. There was a highly statistical difference between SATB2 expression score in CRC cases and non-colonic origin adenocarcinoma group. Highly Statistically significant relation in SATB2 immunoreactivity score in different grades with the highest score in low grade tumors; (95%). Also, there was statistically significant difference in SATB2 immunoreactivity score in different PDC grades with the highest score in grade 1; (82%). Inverse negative correlation between between the PDC tumor grade and SATB2 expression score. Conclusion Positive expression of SATB2 in all studied CRC cases with increase in its expression in low grade CRC and PDC tumor grade. [ABSTRACT FROM AUTHOR]